{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:15:43Z","timestamp":1761920143830},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T00:00:00Z","timestamp":1463616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Inhibikase Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s13365-016-0449-0","type":"journal-article","created":{"date-parts":[[2016,5,19]],"date-time":"2016-05-19T19:24:58Z","timestamp":1463685898000},"page":"871-875","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus"],"prefix":"10.1007","volume":"22","author":[{"given":"Milton H.","family":"Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DeRen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,19]]},"reference":[{"key":"449_CR1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1743-422X-10-298","volume":"10","author":"A Bellizzi","year":"2013","unstructured":"Bellizzi A, Anzivino E, Rodio DM, Cioccolo S, Scrivo R, Morreale M, Pontecorvo S, Ferrari F, Di Nardo G, Nencioni L, Carluccio S, Valesini G, Francia A, Cucchiara S, Palamara AT, Pietropaolo V (2013) Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J 10:298","journal-title":"Virol J"},{"key":"449_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","volume":"74","author":"JR Berger","year":"2013","unstructured":"Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ (2013) JC virus antibody status underestimates infection rates. Ann Neurol 74:84\u201390","journal-title":"Ann Neurol"},{"key":"449_CR3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366:1870\u20131880","journal-title":"N Engl J Med"},{"key":"449_CR4","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1212\/NXI.0000000000000058","volume":"2","author":"V Clausi","year":"2015","unstructured":"Clausi V, Giannecchini S, Magnani E, Repice A, Mechi C, Martelli F, Azzi A, Massacesi L (2015) Markers of JC virus infection in patients with multiple sclerosis under natalizumab therapy. Neurol Neuroimmunol Neuroinflamm 2:e58","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"449_CR5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s13365-014-0268-0","volume":"21","author":"S Delbue","year":"2015","unstructured":"Delbue S, Elia F, Carloni C, Pecchenini V, Franciotta D, Gastaldi M, Colombo E, Signorini L, Carluccio S, Bellizzi A, Bergamaschi R, Ferrante P (2015) JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J Neurovirol 21:645\u2013652","journal-title":"J Neurovirol"},{"key":"449_CR6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s11481-013-9496-y","volume":"8","author":"MI Dom\u00ednguez-Mozo","year":"2013","unstructured":"Dom\u00ednguez-Mozo MI, Garcia-Montojo M, De Las HV, Garcia-Martinez A, Arias-Leal AM, Casanova I, Arroyo R, Alvarez-Lafuente R (2013) Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish multiple sclerosis patients treated with natalizumab. J Neuroimmune Pharmacol 8:1277\u20131286","journal-title":"J Neuroimmune Pharmacol"},{"key":"449_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12834","author":"MI Dom\u00ednguez-Mozo","year":"2015","unstructured":"Dom\u00ednguez-Mozo MI, Garc\u00eda-Montojo M, Arias-Leal A, Garc\u00eda-Mart\u00ednez \u00c1, Santiago JL, Casanova I, Gal\u00e1n V, Arroyo R, Fern\u00e1ndez-Arquero M, Alvarez-Lafuente R (2015) Monitoring John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients. Eur J Neurol. doi: 10.1111\/ene.12834","journal-title":"Eur J Neurol"},{"key":"449_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/infdis\/jir198","volume":"204","author":"L Gorelik","year":"2011","unstructured":"Gorelik L, Reid C, Testa M, Brickelmaier M, Bossolasco S, Pazzi A, Bestetti A, Carmillo P, Wilson E, McAuliffe M, Tonkin C, Carulli JP, Lugovskoy A, Lazzarin A, Sunyaev S, Simon K, Cinque P (2011) Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis 204:103\u2013114","journal-title":"J Infect Dis"},{"key":"449_CR9","first-page":"807","volume":"10","author":"R Lanzillo","year":"2014","unstructured":"Lanzillo R, Liuzzi R, Vallefuoco L, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, Brescia MV (2014) JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Ther Clin Risk Manag 10:807\u2013814","journal-title":"Ther Clin Risk Manag"},{"key":"449_CR10","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s11481-012-9366-z","volume":"7","author":"A Laroni","year":"2012","unstructured":"Laroni A, Giacomazzi CG, Grimaldi L, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Pal\u00f9 G, Uccelli A, Mancardi GL, Varnier OE (2012) Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol 7:665\u2013672","journal-title":"J Neuroimmune Pharmacol"},{"key":"449_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-311100","author":"C McGuigan","year":"2015","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, Nicholas R, Palace J, Pearson OR, Rog D, Young CA (2015) Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. doi: 10.1136\/jnnp-2015-311100 , Online first October 22, 2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"449_CR12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.chom.2010.09.004","volume":"8","author":"U Neu","year":"2010","unstructured":"Neu U, Maginnis MS, Palma AS, Str\u00f6h LJ, Nelson CD, Feizi T, Atwood WJ, Stehle T (2010) Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe 8:309\u2013319","journal-title":"Cell Host Microbe"},{"key":"449_CR13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76:802\u2013812","journal-title":"Ann Neurol"},{"key":"449_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir256","volume":"204","author":"CE Reid","year":"2011","unstructured":"Reid CE, Li H, Sur G, Carmillo P, Bushnell S, Tizard R, McAuliffe M, Tonkin C, Simon K, Goelz S, Cinque P, Gorelik L, Carulli JP (2011) Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis 204:237\u2013244","journal-title":"J Infect Dis"},{"key":"449_CR15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/jnnp.2009.201079","volume":"81","author":"L Rinaldi","year":"2010","unstructured":"Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Pal\u00fa G, Gallo P (2010) No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry 81:1345\u20131350","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"449_CR16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.22107","volume":"68","author":"RA Rudick","year":"2010","unstructured":"Rudick RA, O\u2019Connor PW, Polman CH, Goodman AD, Ray SS, Griffith NM, Jurgensen SA, Gorelik L, Forrestal F, Sandrock AW, E Goelz S (2010) Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 68:304\u2013310","journal-title":"Ann Neurol"},{"key":"449_CR17","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jviromet.2004.06.021","volume":"121","author":"C Ryschkewitsch","year":"2004","unstructured":"Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO (2004) Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 121:217\u2013221","journal-title":"J Virol Methods"},{"key":"449_CR18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1136\/jcp.2009.074864","volume":"63","author":"BK Saundh","year":"2010","unstructured":"Saundh BK, Tibble S, Baker R, Sasnauskas K, Harris M, Hale A (2010) Different patterns of BK and JC polyomavirus reactivation following renal transplantation. J Clin Pathol 63:714\u2013718","journal-title":"J Clin Pathol"},{"key":"449_CR19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070950","volume":"8","author":"T Loy Van","year":"2013","unstructured":"Van Loy T, Thys K, Tritsmans L, Stuyver LJ (2013) Quasispecies analysis of JC virus DNA present in urine of healthy subjects. PLoS One 8, e70950","journal-title":"PLoS One"},{"key":"449_CR20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1128\/JVI.02565-14","volume":"89","author":"T Loy Van","year":"2015","unstructured":"Van Loy T, Thys K, Ryschkewitsch C, Lagatie O, Monaco MC, Major EO, Tritsmans L, Stuyver LJ (2015) JC virus quasispecies analysis reveals a complex viral population underlying progressive multifocal leukoencephalopathy and supports viral dissemination via the hematogenous route. J Virol 89:1340\u20131347","journal-title":"J Virol"},{"key":"449_CR21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.24371","volume":"77","author":"HS Wollebo","year":"2015","unstructured":"Wollebo HS, White MK, Gordon J, Berger JR, Khalili K (2015) Persistence and pathogenesis of the neurotropic polyomavirus JC. Ann Neurol 77:560\u2013570","journal-title":"Ann Neurol"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0449-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-016-0449-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0449-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-016-0449-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:17:27Z","timestamp":1553613447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-016-0449-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,19]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s13365-016-0449-0","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,19]]}}}